|
Demographics
1.
In which region of the
country do you practice?
N=98
2.
How many years have you
been practicing interventional
N=105
cardiology?
3.
What type of practice are
you in?
N=105
4.
What is your practice
ownership?
N=105
General Practices
5.
How many interventional
coronary procedures in TOTAL does your
N=102
institution perform per year?
6.
How many interventional
coronary procedures in TOTAL do you
N=103
personally
perform per year?
Of the total coronary stent procedures that you
perform annually,
what percent are…
7.
Primary stent procedures?
N=99
8.
SVG graft stents?
N=97
9.
Single vessel stent
procedures?
N=98
10.
Re-do stent procedures?
N=96
11.
Multi-vessel stent
procedures
N=97
12.
Left main coronary artery
disease?
N=89
13.
Is Fast CT available in
your institution?
N=95
14.
Is IVUS available in your
institution?
N=102
15.
Is MRA available in your
institution?
N=96
Current Stent Practices and Preferences
16.
Top 10 stents used by
interventional cardiologists in 2002
N=104
(Manufacturer and product).
17.
Top 10 stents used by
interventional cardiologists as a percent of the
N=104
total population, 2002.
18.
Have you been involved in
any stent clinical trials in the last 2 to 3
N=105
years?
19.
Which stent clinical
trials were you involved in over the last 2 to 3 N=38 mentions
years? (Open-ended question)
20.
Have you been involved in
any drug-eluting stent clinical trials in
N=105
the last 2 to 3 years?
21.
Which drug-eluting stent
clinical trials were you involved in over
N=24 mentions
the last 2 to 3 years? (Open-ended question)
22.
Which of the following
vessels/indications will see the MOST growth in N=104
stent usage/application over the next 2 to 3 years?
Brachytherapy and Restenosis
23.
Have you been involved in
any intracoronary brachytherapy clinical N=105
trials in the last 2 to 3 years?
24.
Which intracoronary
brachytherapy clinical trials were you involved N=20 mentions
in over the last 2 to 3 years?
(Open-ended question)
25.
How effective is stent-delivered
radiation in preventing/treating N=81 restenosis?
26.
How effective is
catheter-delivered radiation in preventing/treating N=96 restenosis?
27.
Over the next 2 to 3
years, do you see your use of stent-delivered
N=80
brachytherapy for treating
restenosis increasing, staying the same or
decreasing?
28.
Over the next 2 to 3
years, do you see your use of catheter-delivered N=92
brachytherapy for treating restenosis increasing, staying the same
or
decreasing?
Restenosis Alternatives
29.
How effective is
angioplasty WITH stenting in preventing/treating N=102 restenosis?
30.
How effective is
angioplasty WITHOUT stenting in preventing/treating N=101
restenosis?
31.
How effective is cutting
balloon angioplasty in preventing/treating
N=100 restenosis?
32.
How effective are
atherectomy devices in preventing/treating N=101 restenosis?
33.
Over the next 2 to 3
years, do you see your use of atherectomy
N=98
devices for treating restenosis increasing, staying the same or
decreasing?
34.
Over the next 2 to 3
years, do you see your use of angioplasty
N=102
WITH stenting
for treating restenosis increasing, staying the same
or decreasing?
35.
Over the next 2 to 3
years, do you see your use of angioplasty
N=101
WITHOUT stenting for treating restenosis increasing, staying
the
same or decreasing?
36.
Over the next 2 to 3
years, do you see your use of cutting balloon N=101
angioplasty for treating restenosis increasing, staying the
same
or decreasing?
Stents
and Restenosis
37.
How effective are coated
stents in preventing/treating restenosis?
N=91
38.
How effective are
drug-eluting stents in preventing/treating
N=97
restenosis?
39.
How effective are
biodegradable stents in preventing/treating N=62
restenosis?
40.
How effective is drug
therapy in preventing/treating restenosis?
N=99
41.
A comparison of mean
effectiveness ratings for treatments in
preventing/treating restenosis (includes drug-eluting stents,
catheter-delivered radiation, angioplasty with stenting, cutting
balloon
angioplasty, coated stents, biodegradable stents, stent-delivered
radiation, atherectomy devices, drug therapy, and angioplasty
without
stenting).
42.
Over the next 2 to 3
years, do you see your use of coated stents
N=94
(e.g, heparin, phosphorylcholine, gold) for treating
restenosis increasing,
staying the same, or decreasing?
43.
Over the next 2 to 3
years, do you see your use of drug-eluting stents N=96
for treating restenosis increasing, staying the same, or
decreasing?
44.
Over the next 2 to 3
years, do you see your use of biodegradable
N=64
stents for treating restenosis
increasing, staying the same, or
decreasing?
45.
Over the next 2 to 3
years, do you see your use of drug therapy N=101
(NSAIDs, anti-platlet agents, etc.) for treating restenosis
increasing,
staying the same, or decreasing?
When performing coronary stenting procedures, what
percent of the time do
you use the following thrombolytics?
46.
Cor/Integrilin
N=93
47.
Lilly/Reopro
N=98
48.
Merck/Aggrastat
N=50
49.
Other GP IIb-IIIa
inhibitors
N=11
50.
What is the MOST
important characteristic when deciding to choose a N=104
coronary stent?
51.
What issues, if any do
you believe still need to be resolved with
N=110 mentions
drug-eluting stents? (Open-ended
question)
Physician Stent Preferences: Guidant
52.
Do you currently use GDT
Multilink Penta stent?
N=104
53.
Do you currently use GDT
Multilink Tetra stent?
N=104
54.
Do you currently use GDT
Multilink Pixel stent?
N=104
55.
Do you currently use GDT
Multilink Tristar stent?
N=104
56.
Do you currently use GDT
Multilink Ultra stent?
N=104
57.
Based on your personal
experience, word of mouth and research to N=80
date,
what is your impression regarding the promise of the Cook
Paclitaxel Logic stent to reduce restenosis?
Physician Stent Preferences: Cordis J&J
58.
Do you currently use
Cordis/JNJ BX Velocity stent?
N=104
59.
Do you currently use
Cordis/JNJ BX Velocity Hepacoat stent?
N=104
60.
Do you currently use
Cordis/JNJ Crossflex LC stent?
N=104
61.
Based on your personal
experience, word of mouth and research to N=104
date, what is your impression regarding the promise of the JNJ/Cordis
Sirolimus (Rapamycin)/BX Velocity stent to reduce restenosis?
Physician Stent Preferences: Medtronic AVE
62.
Do you currently use
Medtronic S7 stent?
N=104
63.
Do you currently use
Medtronic S670 stent?
N=104
64.
Do you currently use
Medtronic S660 stent?
N=104
65.
Do you currently use
Medtronic S540 stent?
N=104
66.
Based on your personal
experience, word of mouth and research to
N=46
date, what is your
impression regarding the promise of the Medtronic
Nitric Oxide stent to
reduce restenosis?
Physician
Stent Preferences: Boston Scientific
67.
Do you currently use BSX
Niroyal Elite stent?
N=104
68.
Do you currently use
BSX Nir Elite stent?
N=104
69.
Do you currently use BSX
Niroyal Elite Stainless stent?
N=104
70.
Do you currently use BSX
Niroyal Advance stent?
N=104
71.
Based on your personal
experience, word of mouth and research to
N=98
date, what is your impression
regarding the promise of the BSX
Paclitaxel/NIR stent to reduce restenosis?
Physician Stent Preferences: Abbott Vascular
72.
Do you currently use
Abbott/Biocompatibles BiodivYsio-AS stent?
N=104
Emerging or Alternative Restenosis Technologies
73.
Do you currently use
other stents not mentioned?
N=104
74.
Based on your personal
experience, word of mouth and research to
N=32
date, what is your impression
regarding the promise of the STS
Biopolymers Medi-coat stent to reduce restenosis?
75.
Based on what you have
heard or read about photoangioplasty, what N=101
is your initial impression regarding its promise to reduce
restenosis?
76.
Based on what you have
heard or read about sonotherapy what is
N=103
your initial impression
regarding its promise to reduce restenosis?
77.
Based on what you have
heard or read about cryoplasty what is your
N=101
initial impression regarding its promise to reduce restenosis?
78.
In your opinion, what is
the likelihood of success for cryotherapy for
N=100
the treatment of restenosis?
79.
Based on what you have
heard or read about hyperthermia, what is
N=99
your initial impression regarding its promise to reduce restenosis?
80.
Based on what you have
heard or read about gene therapy/anti-sense N=103
drugs, what is your initial impression regarding its promise to
reduce
restenosis?
81.
Based on what you have
heard or read about halofuginone drug-eluting N=101
stent, what is your initial impression regarding its promise to
reduce
restenosis?
82.
Based on what you have
heard or read about liposomal prostaglandin
N=99
E1, what is your initial
impression regarding its promise to reduce
restenosis?
83.
Based on what you have
heard or read about polymer-based drug N=103
delivery, what is your initial impression regarding its promise to
reduce
restenosis?
84.
Based on your personal
experience, word of mouth and research to
N=38
date, what is your impression
regarding the promise of the Igaki-Tamai
biodegradable stent to reduce restenosis?
85.
Based on what you have
heard or read about vascular endothelial N=104
growth factors (VEGF), what is your initial impression regarding
the
promise to reduce restenosis?
86.
In your opinion, what is
the likelihood of success for intravascular N=100
ultrasound for the treatment of restenosis?
87.
In your opinion, what is
the likelihood of success for photoangioplasty
N=100
for the treatment of restenosis?
88.
A comparison of
treatments in development regarding their promise to
prevent/treat restenosis (includes polymer-based drug delivery,
VEGF,
gene therapy/anti-sense drugs, sonotherapy, liiposomal
prostaglandin
E1, halofuginone DES, cryoplasty, photoangioplasty, and hyperthermia).
© 2002, Medtech Insight, LLC
|
